Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome

In this study, the investigators plan to compare the incidence and complications of intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients taking tamsulosin (Flomax) and treated with retrobulbar injection of anesthesia, versus injection of Healon 5 viscoelastic into the anterior chamber...

Date First Received: February 25, 2008

Last Updated: September 5, 2008

Verified by: Penn State University, January 2008

Clinical Trial Phase: N/A | Start Date: February 2008

Overall Status: Recruiting

Estimated Enrollment: 100

Brief Summary

Official Title: “Retrobulbar Injection of Anesthesia Versus Injection of Healon 5 Viscoelastic Into the Anterior Chamber in the Management of Intraoperative Floppy Iris Syndrome”

Condition Keyword(s):

In this study, the investigators plan to compare the incidence and complications of intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients taking tamsulosin (Flomax) and treated with retrobulbar injection of anesthesia, versus injection of Healon 5 viscoelastic into the anterior chamber.

Study Type: Interventional

Study Design: Prevention, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: May 2010

Intervention(s) in this Clinical Trial

  • Procedure: Healon 5 injection
    • Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
  • Procedure: Retrobulbar anesthetic injection
    • 3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: 1
    • Healon 5
  • Experimental: 2
    • Retrobulbar Anesthetic Injection

Outcome Measures for this Clinical Trial

Primary Measures

  • Preoperative pupil diameter, pupil diameter after hydrodissection, pupil diameter after nuclear removal, pupil diameter after cortex removal, and pupil diameter at conclusion of surgery.
    • Time Frame: 2 years
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • All cataract patients taking tamsulosin

Exclusion Criteria:

  • Patients with any history of iridocyclitis
  • Presence of iris neovascularization
  • History of prior iris surgery
  • Presence of traumatic cataracts
  • Presence of zonular dialysis

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Penn State University

Overall Clinical Trial Officials and Contacts

Ahmad A Aref, M.D. Principal Investigator The Penn State Hershey Eye Center  

Overall Contact: Ahmad A Aref, M.D. (717) 531-8783 aaref@hmc.psu.edu

Related Publications

References

Chang DF, Osher RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology. 2007 May;114(5):957-64.

Additional Information

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00627913

Study ID Number: 27170

ClinicalTrials.gov Identifier: NCT00627913

Health Authority: United States: Institutional Review Board

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.